Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Outcomes of intravenous tissue plasminogen activator for acute ischaemic stroke in HIV-infected adults.

Sweeney EM, Thakur KT, Lyons JL, Smith BR, Willey JZ, Cervantes-Arslanian AM, Hickey MK, Uchino K, Haussen DC, Koch S, Schwamm LH, Elkind MS, Shinohara RT, Mateen FJ.

Eur J Neurol. 2014 Nov;21(11):1394-9. doi: 10.1111/ene.12506. Epub 2014 Jul 10.

PMID:
25040336
2.
3.

Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.

Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2014 Apr 23-30;311(16):1632-40. doi: 10.1001/jama.2014.3203.

PMID:
24756513
4.

Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.

Xian Y, Federspiel JJ, Grau-Sepulveda M, Hernandez AF, Schwamm LH, Bhatt DL, Smith EE, Reeves MJ, Thomas L, Webb L, Bettger JP, Laskowitz DT, Fonarow GC, Peterson ED.

JAMA Neurol. 2016 Jan;73(1):50-9. doi: 10.1001/jamaneurol.2015.3106.

PMID:
26551916
5.

Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?

Hassan AE, Chaudhry SA, Jani V, Grigoryan M, Khan AA, Adil MM, Qureshi AI.

J Stroke Cerebrovasc Dis. 2013 May;22(4):545-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.022. Epub 2013 Feb 28.

PMID:
23453555
6.

Safety of off-label stroke treatment with tissue plasminogen activator.

Kvistad CE, Logallo N, Thomassen L, Waje-Andreassen U, Brøgger J, Naess H.

Acta Neurol Scand. 2013 Jul;128(1):48-53. doi: 10.1111/ane.12076. Epub 2013 Jan 11.

PMID:
23311439
7.

Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy.

Masrur S, Abdullah AR, Smith EE, Hidalgo R, El-Ghandour A, Rordorf G, Schwamm LH.

J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):124-30. doi: 10.1016/j.jstrokecerebrovasdis.2009.10.010. Epub 2010 Jul 3.

PMID:
20598579
8.

Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.

Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED.

JAMA. 2012 Jun 27;307(24):2600-8. doi: 10.1001/jama.2012.6756.

PMID:
22735429
9.

Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.

Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC.

Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):543-9. doi: 10.1161/CIRCOUTCOMES.111.000303.

10.

Determinants of early outcomes in patients with acute ischemic stroke and proximal artery occlusion.

LaBuzetta JN, Yoo AJ, Ali S, Fitzpatrick K, Leslie-Mazwi T, Hirsch JA, Schwamm L, Rost N.

J Stroke Cerebrovasc Dis. 2014 Nov-Dec;23(10):2527-32. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.020. Epub 2014 Sep 18.

11.

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH.

JAMA. 2013 Jun 19;309(23):2480-8. doi: 10.1001/jama.2013.6959.

PMID:
23780461
12.

Outcomes of endovascular versus intravenous thrombolytic treatment for acute ischemic stroke in dialysis patients.

Saeed F, Adil MM, Piracha BH, Qureshi AI.

Int J Artif Organs. 2014 Oct;37(10):727-33. doi: 10.5301/ijao.5000349. Epub 2014 Sep 27.

13.

Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.

Lubeck DP, Danese MD, Duryea J, Halperin M, Tayama D, Yu E, Lalla D, Grotta JC.

Int J Stroke. 2016 Feb;11(2):198-205. doi: 10.1177/1747493015609776.

PMID:
26783311
14.

Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.

Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV.

Arch Neurol. 2001 Dec;58(12):2009-13.

PMID:
11735774
15.

Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.

Wolfe T, Suarez JI, Tarr RW, Welter E, Landis D, Sunshine JL, Zaidat OO.

J Stroke Cerebrovasc Dis. 2008 May-Jun;17(3):121-8. doi: 10.1016/j.jstrokecerebrovasdis.2007.12.004.

PMID:
18436152
16.

Intra-arterial therapy for acute ischemic stroke under general anesthesia versus monitored anesthesia care.

John S, Thebo U, Gomes J, Saqqur M, Farag E, Xu J, Wisco D, Uchino K, Hussain MS.

Cerebrovasc Dis. 2014;38(4):262-7. doi: 10.1159/000368216. Epub 2014 Nov 13.

PMID:
25401730
17.

Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).

Marsh EB, Gottesman RF, Hillis AE, Urrutia VC, Llinas RH.

Medicine (Baltimore). 2013 Nov;92(6):317-23. doi: 10.1097/MD.0000000000000006.

18.

Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.

Sahlas DJ, Gould L, Swartz RH, Mohammed N, McNicoll-Whiteman R, Naufal F, Oczkowski W.

J Stroke Cerebrovasc Dis. 2014 Jan;23(1):155-9. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.004. Epub 2013 Jan 31.

PMID:
23375748
19.

Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older.

Mateen FJ, Nasser M, Spencer BR, Freeman WD, Shuaib A, Demaerschalk BM, Wijdicks EF.

Mayo Clin Proc. 2009 Apr;84(4):334-8. doi: 10.1016/S0025-6196(11)60542-9.

20.

Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.

Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ.

Cerebrovasc Dis. 2010 Feb;29(3):263-7. doi: 10.1159/000275500. Epub 2010 Jan 15.

PMID:
20090317

Supplemental Content

Support Center